Commentary: Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome

Frontiers in Cellular and Infection Microbiology

Volumn 8, Issue APR, 2018, Pages

  Anonye, Blessing O ^a,b  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Bacteriophages; C. difficile infection; Caudovirales; Fecal microbiota transplantation; Gut microbiota

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; RNA 16S; VANCOMYCIN;

BACTERIAL COLONIZATION; BACTERIOPHAGE; CAUDOVIRALES; CLOSTRIDIUM DIFFICILE INFECTION; FECAL MICROBIOTA TRANSPLANTATION; GENE SEQUENCE; HUMAN; METAGENOMICS; MICROVIRIDAE; NONHUMAN; NOTE; TREATMENT OUTCOME; VIRUS LIKE AGENT; CLOSTRIDIUM INFECTION;

BACTERIOPHAGES; CLOSTRIDIUM INFECTIONS; FECAL MICROBIOTA TRANSPLANTATION; HUMANS; TREATMENT OUTCOME;

EID: 85045002997     PISSN: None     EISSN: 22352988     Source Type: Journal    
DOI: 10.3389/fcimb.2018.00104     Document Type: Note

References (19)

1. Broecker, F., Klumpp, J., and Moelling, K. (2016a). Long-term microbiota and virome in a Zürich patient after fecal transplantation against Clostridium difficile infection. Ann. N. Y. Acad. Sci. 1372, 29-41. doi: 10.1111/nyas.13100
2. Broecker, F., Klumpp, J., Schuppler, M., Russo, G., Biedermann, L., Hombach, M., et al. (2016b). Long-term changes of bacterial and viral compositions in the intestine of a recovered Clostridium difficile patient after fecal microbiota transplantation. Cold Spring Harb. Mol. Case Stud. 2:a000448. doi: 10.1101/mcs.a000448
3. Broecker, F., Russo, G., Klumpp, J., and Moelling, K. (2017). Stable core virome despite variable microbiome after fecal transfer. Gut Microbes 8, 214-220. doi: 10.1080/19490976.2016.1265196
4. Fuentes, S., van Nood, E., Tims, S., Heikamp-de Jong, I., ter Braak, C. J., Keller, J. J., et al. (2014). Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection. ISME J. 8, 1621-1633. doi: 10.1038/ismej.2014.13
5. Jiang, Z. D., Ajami, N. J., Petrosino, J. F., Jun, G., Hanis, C. L., Shah, M., et al. (2017). Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection-fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. Aliment. Pharmacol. Ther. 45, 899-908. doi: 10.1111/apt.13969
6. Kim, M. S., Park, E. J., Roh, S. W., and Bae, J. W. (2011). Diversity and abundance of single-stranded DNA viruses in human feces. Appl. Environ. Microbiol. 77, 8062-8070. doi: 10.1128/aem.06331-11
7. Ly, M., Jones, M. B., Abeles, S. R., Santiago-Rodriguez, T. M., Gao, J., Chan, I. C., et al. (2016). Transmission of viruses via our microbiomes. Microbiome 4, 64. doi: 10.1186/s40168-016-0212-z
8. Manrique, P., Bolduc, B., Walk, S. T., van der Oost, J., de Vos, W. M., and Young, M. J. (2016). Healthy human gut phageome. Proc. Natl. Acad. Sci. U.S.A. 113, 10400-10405. doi: 10.1073/pnas.1601060113
9. Meader, E., Mayer, M. J., Gasson, M. J., Steverding, D., Carding, S. R., and Narbad, A. (2010). Bacteriophage treatment significantly reduces viable Clostridium difficile and prevents toxin production in an in vitro model system. Anaerobe 16, 549-554. doi: 10.1016/j.anaerobe.2010.08.006
10. Meader, E., Mayer, M. J., Steverding, D., Carding, S. R., and Narbad, A. (2013). Evaluation of bacteriophage therapy to control Clostridium difficile and toxin production in an in vitro human colon model system. Anaerobe 22, 25-30. doi: 10.1016/j.anaerobe.2013.05.001
11. Nale, J. Y., Chutia, M., Carr, P., Hickenbotham, P. T., and Clokie, M. R. (2016a). 'Get in early'; biofilm and Wax Moth (Galleria mellonella) models reveal new insights into the therapeutic potential of Clostridium difficile bacteriophages. Front. Microbiol. 7:1383. doi: 10.3389/fmicb.2016.01383
12. Nale, J. Y., Redgwell, T. A., Millard, A., and Clokie, M. R. J. (2018). Efficacy of an optimised bacteriophage cocktail to clear Clostridium difficile in a batch fermentation model. Antibiotics 7:13. doi: 10.3390/antibiotics7010013
13. Nale, J. Y., Spencer, J., Hargreaves, K. R., Buckley, A. M., Trzepinski, P., Douce, G. R., et al. (2016b). Bacteriophage combinations significantly reduce clostridium difficile growth in vitro and proliferation in vivo. Antimicrob. Agents Chemother. 60, 968-981. doi: 10.1128/aac.01774-15
14. Norman, J. M., Handley, S. A., Baldridge, M. T., Droit, L., Liu, C. Y., Keller, B. C., et al. (2015). Disease-specific Alterations in the enteric virome in inflammatory bowel disease. Cell 160, 447-460. doi: 10.1016/j.cell.2015.01.002
15. Ott, S. J., Waetzig, G. H., Rehman, A., Moltzau-Anderson, J., Bharti, R., Grasis, J. A., et al. (2017). Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile Infection. Gastroenterology 152, 799.e797-811.e797. doi: 10.1053/j.gastro.2016.11.010
16. Seekatz, A. M., Aas, J., Gessert, C. E., Rubin, T. A., Saman, D. M., Bakken, J. S., et al. (2014). Recovery of the gut microbiome following fecal microbiota transplantation. MBio 5:e00893-14. doi: 10.1128/mBio.00893-14
17. Staley, C., Kelly, C. R., Brandt, L. J., Khoruts, A., and Sadowsky, M. J. (2016). Complete microbiota engraftment is not essential for recovery from recurrent Clostridium difficile infection following fecal microbiota transplantation. MBio 7:e01965-16. doi: 10.1128/mBio.01965-16
18. van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., et al. (2013). Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407-415. doi: 10.1056/NEJMoa1205037
19. Zuo, T., Wong, S. H., Lam, K., Lui, R., Cheung, K., Tang, W., et al. (2017). Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome. Gut 67, 634-643. doi: 10.1136/gutjnl-2017-313952